Sugi Predict

Sugi Predict / Compounds / SCHEMBL5688462

SCHEMBL5688462

SCHEMBL5688462

Cc1ccnc(Cc2ccc(OC(=O)N3CCC(Sc4nccn4C)CC3)cc2)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NOS1 P29475 2/20 0.38
▸ NOS2 P35228 2/20 0.38
▸ NOS3 P29474 1/20 0.38
▸ TLR9 Q9NR96 1/20 0.35
▸ TLR8 Q9NR97 1/20 0.35
▸ TLR7 Q9NYK1 1/20 0.35
▸ KEAP1 Q14145 1/20 0.35
▸ NFE2L2 Q16236 1/20 0.35
▸ P2RX3 P56373 1/20 0.35
▸ POLB P06746 1/20 0.34
▸ BCHE P06276 2/20 0.34
▸ CNR2 P34972 2/20 0.34
▸ NPC1 O15118 2/20 0.34
▸ RAB9A P51151 2/20 0.34
▸ CYP1A2 P05177 1/20 0.34
▸ CYP2C9 P11712 1/20 0.34
▸ CYP2C19 P33261 1/20 0.34
▸ GAA P10253 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ GRIN2B Q13224 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5931588 0.92 NOS1 (0.38) NOS1NOS2NOS3TLR9TLR8
SCHEMBL5687985 0.88 CHRM5 (0.46) NOS1NOS2NOS3P2RX3POLB
SCHEMBL5687461 0.88 CYP1A2 (0.36) TLR9TLR8TLR7KEAP1NFE2L2
SCHEMBL5690537 0.88 GAA (0.39) NOS2NPC1RAB9ACYP1A2CYP2C9
SCHEMBL5690378 0.86 NOS3 (0.37) NOS1NOS2NOS3TLR9TLR8
SCHEMBL5688037 0.85 KMT2A (0.35) POLBBCHECNR2NPC1RAB9A
SCHEMBL5687777 0.82 SMO (0.38) POLBNPC1RAB9AGAASMN1; SMN2
SCHEMBL5931868 0.82 NOS1 (0.38) NOS1NOS2NOS3TLR9TLR8
SCHEMBL5689173 0.82 NOS1 (0.38) NOS1NOS2NOS3TLR9TLR8
SCHEMBL5931506 0.82 SMN1; SMN2 (0.52) POLBNPC1RAB9AGAASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060160851-A1 Substituted piperidine carbamates NOVO NORDISK A/S (DK) 2006-07-20 — — US claimed
EP-1636207-A1 SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 — — EP claimed
WO-2004111032-A1 SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 — — WO claimed
US-20060160851-A1 Substituted piperidine carbamates NOVO NORDISK A/S (DK) 2006-07-20 — — US disclosed
EP-1636207-A1 SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 — — EP disclosed
WO-2004111032-A1 SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160851-A1 Substituted piperidine carbamates LIPE, PNLIP, LIPC NOS1 646/4885NOS2 797/4885NOS3 444/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.